NCM · Financial Statements

Curanex Pharmaceuticals Inc (CURX) Financial Statements

$4.64 NCM: CURX Market Cap $7.28M

Curanex Pharmaceuticals Inc most recently reported annual revenue of $0, a net loss of $4.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Curanex Pharmaceuticals Inc: net profit was positive in 0 of 4 reported years; the most recent year shows a net loss of $4.0M.

Income Statement — 4 Years (USD millions)

Metric2022202320242025
Revenue$0$0$0$0
Operating Expenses$0$0$0$4.0M
Operating Profit$0$0$0$-4.0M
Operating Margin-77.8%0.0%0.0%0.0%
Other Income$0$0$0$0
Interest$0$0$0$0
Depreciation$0$0$0$0
Profit Before Tax$0$0$0$-4.0M
Tax$0$0$0$0
Net Profit$0$0$0$-4.0M
EPS$-0.01$-0.01$-0.26$-2.98
Dividend Payout0.0%0.0%0.0%0.0%

Quarterly Results — Last 11 Quarters (USD millions)

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$0$0$0$0$0$0$0$1.0M$3.0M$3.0M$3.0M
Operating Profit$0$0$0$0$0$0$0$-1.0M$-3.0M$-3.0M$-3.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$0$0$0$0$0$0$0$-1.0M$-3.0M$-3.0M$-3.0M
Tax$0$0$0$0$0$0$0$0$0$0$0
Net Profit$0$0$0$0$0$0$0$-1.0M$-3.0M$-3.0M$-3.0M
EPS$-0.01$-0.06$-0.03$-0.07$-0.10$-0.10$-0.04$-0.67$-2.17$-2.22$-2.32

Over the 4 years reported for Curanex Pharmaceuticals Inc, cash stood at $5.0M in the latest year, shareholders' equity was $0.

Balance Sheet — 4 Years (USD millions)

Metric2022202320242025
Total Assets—$0$1.0M$12.0M
Current Assets—$0$1.0M$11.0M
Cash—$0$0$5.0M
Inventory—$0$0$0
Receivables—$0$0$0
Fixed Assets—$0$0$0
Capital Work in Progress$0$0$0$0
Investments$0$0$0$0
Other Assets—$0$0$0
Total Liabilities—$0$0$0
Current Liabilities—$0$0$0
Borrowings$0$0$0$0
Other Liabilities—$0$0$0
Equity—$0$0$0
Reserves—$0$1.0M$11.0M

For Curanex Pharmaceuticals Inc, operating cash flow was positive in 0 of 4 reported years; free cash flow in the latest year was negative at $10.0M; free cash flow was positive in 0 of 4 years.

Cash Flow Statement — 4 Years (USD millions)

Metric2022202320242025
Operating Cash Flow—$0$-1.0M$-10.0M
Investing Cash Flow—$0$0$0
Financing Cash Flow—$0$0$0
Net Cash Flow—$0$0$5.0M
Free Cash Flow$0$0$-1.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.39
FCF Yield-180.60%
Quick Ratio45.95
Interest Coverage-2580.17
Return 1Y—
Return 3Y—
Return 5Y—

Curanex Pharmaceuticals Inc (CURX) financials — frequently asked questions

What is Curanex Pharmaceuticals Inc's annual revenue?

Curanex Pharmaceuticals Inc (CURX) reported annual revenue of $0 in its most recent fiscal year.

What is Curanex Pharmaceuticals Inc's net profit?

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $4.0M in its most recent fiscal year.

What is CURX EV/EBITDA?

Curanex Pharmaceuticals Inc's enterprise value to EBITDA (EV/EBITDA) ratio is -0.39. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
CURX Overview CURX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.